3 июл. 2024 г. · The U.S. Food and Drug Administration on Tuesday approved Eli Lilly's treatment for early Alzheimer's, making it the second therapy for ...

2 июл. 2024 г. · Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease ; Length of Treatment. 6 months.

2 июл. 2024 г. · The Food and Drug Administration on Tuesday approved Eli Lilly 's Alzheimer's drug donanemab, expanding the limited treatment options for the mind-wasting ...

13 сент. 2024 г. · FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis.

The U.S. Food and Drug Administration (FDA) has approved a new drug to treat Alzheimer's disease called donanemab under the brand name Kisunla.

3 июл. 2024 г. · As of July 2, the FDA has approved donanemab for adults with early symptomatic Alzheimer's disease, mild cognitive impairment, and mild dementia ...

2 июл. 2024 г. · According to Eli Lilly, Kisunla slowed cognitive and functional decline by up to 35% after 18 months, compared to patients who took a placebo.

2 июл. 2024 г. · The FDA approved a new Alzheimer's drug that has been shown in clinical trials to modestly slow a decline in memory and thinking abilities.

13 сент. 2024 г. · Eli Lilly (LLY.N) said on Friday the US Food and Drug Administration approved its eczema drug for use in adults and children above 12 years old.

2 июл. 2024 г. · Lilly Wins FDA Approval for New Drug to Slow Alzheimer's. Doctors can stop drug if amyloid drops to minimal levels; Drug to cost $32,000 for the ...